- Home
- SLGL vs STRO Comparison
SLGL vs STRO Comparison
Compare SLGL & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLGL
- STRO
- Stock Information
- Founded
- SLGL 1997
- STRO 2003
- Country
- SLGL Israel
- STRO United States
- Employees
- SLGL N/A
- STRO N/A
- Industry
- SLGL Biotechnology: Pharmaceutical Preparations
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SLGL Health Care
- STRO Health Care
- Exchange
- SLGL Nasdaq
- STRO Nasdaq
- Market Cap
- SLGL 69.1M
- STRO 76.5M
- IPO Year
- SLGL 2018
- STRO 2018
- Fundamental
- Price
- SLGL $29.01
- STRO $0.84
- Analyst Decision
- SLGL
- STRO Hold
- Analyst Count
- SLGL 0
- STRO 7
- Target Price
- SLGL N/A
- STRO $1.97
- AVG Volume (30 Days)
- SLGL 25.3K
- STRO 558.5K
- Earning Date
- SLGL 08-15-2025
- STRO 11-12-2025
- Dividend Yield
- SLGL N/A
- STRO N/A
- EPS Growth
- SLGL N/A
- STRO N/A
- EPS
- SLGL N/A
- STRO N/A
- Revenue
- SLGL $23,931,000.00
- STRO $104,473,000.00
- Revenue This Year
- SLGL N/A
- STRO $65.48
- Revenue Next Year
- SLGL $31.17
- STRO N/A
- P/E Ratio
- SLGL N/A
- STRO N/A
- Revenue Growth
- SLGL 264.86
- STRO N/A
- 52 Week Low
- SLGL $4.01
- STRO $0.52
- 52 Week High
- SLGL $30.98
- STRO $4.60
- Technical
- Relative Strength Index (RSI)
- SLGL 65.45
- STRO 44.29
- Support Level
- SLGL $23.15
- STRO $0.84
- Resistance Level
- SLGL $30.98
- STRO $0.92
- Average True Range (ATR)
- SLGL 2.27
- STRO 0.08
- MACD
- SLGL 0.00
- STRO -0.01
- Stochastic Oscillator
- SLGL 74.90
- STRO 2.94
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.